GLP-3 5mg
$55.00
Retatrutide is a novel, investigational multireceptor agonist being developed for the treatment of obesity and potentially other metabolic disorders. It is designed to simultaneously target three key metabolic pathways by acting as an agonist at the receptors for glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon. By activating these three distinct receptors, retatrutide aims to offer a synergistic effect on appetite regulation, insulin sensitivity, and overall metabolic function.